Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. - Wikidata - wikimedia - TriplyDB

Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.

Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.

http://www.wikidata.org/entity/Q37386059

about

RETRACTED: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer.The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-β- catenin signaling axis.Retrospective comparative study of the effects of dendritic cell vaccine and cytokine-induced killer cell immunotherapy with that of chemotherapy alone and in combination for colorectal cancer.Increase of cyclooxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancer Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo.The Effect of Helicobacter pylori on Epidermal Growth Factor Receptor-Induced Signal Transduction and the Preventive Effect of Celecoxib in Gastric Cancer Cells Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer.NSAIDs induce apoptosis in nonproliferating ovarian cancer cells and inhibit tumor growth in vivo.Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase II trial in patients with metastatic colorectal adenocarcinoma.A second-generation 15-PGDH inhibitor promotes bone marrow transplant recovery independent of age, transplant dose, and G-CSF support.

P2860

Q24651467-E8916B0B-0F9F-4D3F-8591-DFB512C540DB Q30423537-9F63ACE0-F32F-4FFC-80EB-C94E04F90591 Q33591665-A22AC8FE-2DF0-4416-8B69-039F0421B102 Q34119366-CA61FC08-F45D-4E78-91F4-6FA29236ACAE Q34561552-FA23D49D-83E7-4A37-929D-F0FB4B398576 Q36172737-3245D9FF-0ADD-4209-B3D3-F11BD343FE29 Q37196468-15F2341A-A01C-45F0-BE38-4488F98F4420 Q38002127-4857E5AB-3C98-4547-AC1B-1FDA2B13725C Q39350226-34E0D625-1BAF-400F-B974-D8F393FF4DE2 Q42935094-C81D204E-D28D-4455-A20D-1A8C3843D0D8 Q53082009-A7995B6A-334D-4881-8A02-2AC40615B8DE

P2860

Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.

http://www.wikidata.org/entity/Q37386059

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 April 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phase-II study of dose attenua ...... in advanced colorectal cancer.

@en

Phase-II study of dose attenua ...... in advanced colorectal cancer.

@nl

type

label

Phase-II study of dose attenua ...... in advanced colorectal cancer.

@en

Phase-II study of dose attenua ...... in advanced colorectal cancer.

@nl

prefLabel

Phase-II study of dose attenua ...... in advanced colorectal cancer.

@en

Phase-II study of dose attenua ...... in advanced colorectal cancer.

@nl

P1433

Q37386059-31D3D4E7-540D-4D3D-BA33-923F21010B70

P1476

Q37386059-FFEB8ED6-67B5-478C-8CF1-7720042AF3B7

P2093

Q37386059-1641ECE5-9C55-4BB1-8406-853CE25B74FC

Q37386059-338B8E44-811E-46F7-9482-B4060FBA31DA

Q37386059-515BB899-3C1A-44A6-806D-BB67316E37BB

Q37386059-81ACC33E-57F9-4024-8C62-2BD02AB78DB2

Q37386059-90D6D7A2-5DA3-443C-A9C9-354215DA096B

Q37386059-9182FF45-A9E0-4491-A4FA-DC623FA614BD

Q37386059-AF7EA302-406A-4722-98CD-1571790EFF1B

Q37386059-BAC6CFCF-16C1-4E7B-8555-65712877F27A

Q37386059-C8813810-12A5-4C6B-BCAB-EE12E563EA8A

Q37386059-FC7C788E-141A-40FC-8879-474AA18A2EB4

P2860

Q37386059-0CBCF6B4-73B7-4240-B5C0-DDCC4DF18E5F

Q37386059-17DE855B-896E-458F-AB06-28CED63CF7CB

Q37386059-1EBD7DF4-8F10-400A-A107-49C148AAFBBD

Q37386059-2A0DDF72-E502-4AF5-9692-BFDD7B6670E8

Q37386059-2A30CD39-4C27-42B7-BD26-531B0093D899

Q37386059-31D2834E-5AA4-4767-9C10-7FD7583C930E

Q37386059-3296F8EA-1654-4D15-83F7-16430E705D03

Q37386059-45A71779-8168-4323-A50E-03C3F01D8A62

Q37386059-59E4DFE2-26B7-4351-AF2C-B61ABBE98F73

Q37386059-759313BE-5BA5-47B9-867F-516151239922

P2888

Q37386059-91295CB5-1CDB-4579-982C-3509C7EED9D0

P304

Q37386059-CD18473C-50E1-4EE8-9C05-96ADF8111A19

P31

Q37386059-2E5550D7-AE7F-420D-B42A-D8287DDF3B74

P356

Q37386059-7D6CE98D-AF8E-4B9C-AADF-47E0F2282F81

P433

Q37386059-1848FE6C-819D-49B7-AE10-AD782D71BBE5

P478

Q37386059-BBAF8B60-C42D-4C65-9029-13F4BA40DB29

P577

Q37386059-A8CEF554-9E41-47BD-88A5-6BE01B7BDCFF

P698

Q37386059-4058C9CB-D87D-4DDA-9D07-A3CDD808A5FB

P921

Q37386059-EB72F8E7-ECBE-475A-8953-CF46A6BD6050

P932

Q37386059-A4E03FA3-C5FF-4FE2-BD45-B08F3794EADA

P356

S00280-007-0472-1

P1433

Cancer Chemotherapy and Pharmacology

P1476

Phase-II study of dose attenua ...... in advanced colorectal cancer.

@en

P2093

Ann Marie Ferris

http://www.w3.org/2001/XMLSchema#string

Anthony F Shields

http://www.w3.org/2001/XMLSchema#string

Barbara Rusin

http://www.w3.org/2001/XMLSchema#string

Bassel F El-Rayes

http://www.w3.org/2001/XMLSchema#string

Lance K Heilbrun

http://www.w3.org/2001/XMLSchema#string

Mark M Zalupski

http://www.w3.org/2001/XMLSchema#string

Philip A Philip

http://www.w3.org/2001/XMLSchema#string

Raghu Venkatramanamoorthy

http://www.w3.org/2001/XMLSchema#string

Stephanie G Manza

http://www.w3.org/2001/XMLSchema#string

Ulka Vaishampayan

http://www.w3.org/2001/XMLSchema#string

P2860

Cyclooxygenase regulates angiogenesis induced by colon cancer cells

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

Celecoxib leads to G2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner

Cancer statistics, 2006

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

P2888

s00280-007-0472-1

P304

283-289

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-007-0472-1

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P577

2007-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17429629

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

3860285

http://www.w3.org/2001/XMLSchema#string